vTv Therapeutics financials
$30.54+0.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $36.8M | $0.00 | $0.00 | $0.00 | $0.00 | $17.0K | $0.00 | $0.00 | $1.0M | $0.00 | $0.00 |
| Gross profit | $0.00 | $36.8M | $0.00 | $0.00 | $0.00 | $0.00 | $17.0K | $0.00 | $0.00 | $1.0M | $0.00 | $0.00 |
| Gross margin | — | 100.0% | — | — | — | — | 100.0% | — | — | 100.0% | — | — |
| Operating income | -$13.9M | $23.3M | -$8.0M | -$10.7M | -$7.7M | -$6.5M | -$4.9M | -$6.5M | -$7.2M | -$5.6M | -$4.7M | -$5.4M |
| Net income | -$13.1M | $24.1M | -$7.1M | -$8.7M | -$6.0M | -$5.1M | -$3.6M | -$4.8M | -$5.2M | -$4.9M | -$3.5M | -$6.7M |
| Net margin | — | 65.5% | — | — | — | — | −21376.5% | — | — | −486.5% | — | — |
| Diluted EPS | $-1.05 | $1.65 | $-0.57 | $-1.08 | $-0.92 | $-0.77 | $-0.51 | $-0.88 | $-0.81 | $-1.17 | $-1.67 | $-3.19 |
| EBITDA | -$13.9M | $23.3M | -$8.0M | -$10.7M | -$7.7M | -$6.5M | -$4.9M | -$6.5M | -$7.1M | -$5.6M | -$4.7M | -$5.3M |
| Operating cash flow | -$11.4M | $9.2M | -$9.3M | -$5.2M | -$5.1M | -$5.7M | -$4.8M | -$6.4M | -$6.7M | -$7.3M | -$2.9M | -$4.8M |
| Free cash flow | -$11.4M | $9.2M | -$9.3M | -$5.2M | -$5.1M | -$5.7M | -$4.8M | -$6.4M | -$6.7M | -$7.3M | -$2.9M | -$4.8M |
| Diluted shares | 12.4M | 14.6M | 12.5M | 8.1M | 6.6M | 6.6M | 7.1M | 5.5M | 6.4M | 4.1M | 2.1M | 2.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $86.6M | $98.1M | $88.9M | $98.5M | $25.9M | $31.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $328.0K | $0.00 | $0.00 |
| Total assets | $87.6M | $98.8M | $89.9M | $99.5M | $26.4M | $32.0M |
| Total liabilities | $9.0M | $8.9M | $25.5M | $29.0M | $24.0M | $23.1M |
| Shareholders' equity | $78.6M | $90.0M | $64.4M | $70.5M | $2.4M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology